Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging

NCT06369610 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06369610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06369610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 22, 2024
Completion date
July 29, 2028
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate carcinoma, prostate adenocarcinoma